MedTrace Logo

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

NCT02683889 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-03-23

Study results available
· View outcomes & findings →

Summary

This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.

Conditions

  • FSGS

Interventions

DRUG

Acthar

patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Sixto Giusti, MD · University of Colorado, Denver

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2024-06-06
Completion
2024-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02683889 on ClinicalTrials.gov